EMEA-001178-PIP01-11-M04

Key facts

Invented name
Stivarga
Active substance
regorafenib
Therapeutic area
Oncology
Decision number
P/0158/2019
PIP number
EMEA-001178-PIP01-11-M04
Pharmaceutical form(s)
  • Film-coated tablet
  • Granules
Condition(s) / indication(s)
Treatment of all conditions contained in the category of malignant neoplasms (except haematopoietic and lymphoid tissue)
Route(s) of administration
Oral use
Contact for public enquiries
Bayer AG

E-mail: pediatrics.medical-affairs-europe@bayer.com
Tel. +49 3046815333

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating